OmniScreen™
Well-validated in vitro screening program for rapid and cost-effective screening of ~500 cell lines.
Biomarker discovery is crucial for advancing personalized cancer treatments, yet tumor heterogeneity and complex data analysis present significant challenges. Early identification and validation of biomarkers can streamline drug development and enhance clinical outcomes. Crown Bioscience offers an integrated platform spanning in silico, in vitro, ex vivo, and in vivo stages to accelerate biomarker discovery and validation.
Access 1,000+ cancer cell lines, 600+ organoids, and 2,600+ PDX models for streamlined biomarker discovery across preclinical stages.
Select the right screening option tailored to your research phase, from high-throughput cell line screening to advanced PDX mouse clinical trials.
We offer diverse screening solutions across different model systems to meet specific research needs across drug development phases. Whether focusing on cost-efficiency, high throughput, or predictive power, we provide flexibility to help you achieve your goals. Choose from our customized screens or take advantage of our quarterly-run OmniScreen™ (cell line screen) and OrganoidXplore™ (organoid screen) services for rapid and cost-effective data.
Opt for hypothesis-free discovery or targeted biomarker refinement, integrating multi-omics data and efficacy testing for reliable results.
Our bioinformatics team enhances every stage with expert support in model selection, study design, and data interpretation for actionable insights.
Comprehensive lab services in genomics, transcriptomics, proteomics, spatial omics, and more, delivering insights on PD, PK, and mechanisms of action.
Leverage ex vivo patient tissues or our biobank to validate biomarkers and develop clinical assays.
In vitro screening offers a high-throughput, cost-effective platform for early biomarker discovery and refinement, helping identify drug leads, targets, mechanisms of action (MoA), and genetic markers associated with drug response, and guide future in vivo model selection.
Our 2D cell lines and 3D tumor organoids provide rapid, data-driven insights, helping optimize early-stage research decisions.
Fig. Example workflow of in vitro compound screening
Did you know many oncology therapies fail in Phase II clinical trials due to a lack of efficacy? Crown Bioscience’s PDX Mouse Clinical Trials (MCTs) address this challenge by offering a robust, clinically relevant platform designed to improve the predictability of preclinical studies.
Figure. A representative PDX Mouse Clinical Trial Design
With the world’s largest collection of over 2,600 PDX models, our MCTs help bridge the gap between preclinical and clinical stages, enabling:
With 12+ years of experience and over 300 successful MCT projects, Crown Bioscience is your trusted partner, supporting the journey from preclinical studies to clinical validation with unmatched expertise and resources.
Well-validated in vitro screening program for rapid and cost-effective screening of ~500 cell lines.
Preclinical oncology drug development and validation using tumor organoids and the HUB tumor organoid biobank.
Translational Models, Predictive Biomarkers, New Indications, Deeper Drug Insights.
Fast, reliable, accurate, and cost-effective laboratory services for data-driven decisions to meet your specific needs.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-11-05
2023-03-05
site_page
Integrated Solutions - Translational Biomarker